PHIO | tickerfilter.com

Fundamental analysis

26%

Profitability 25%

Dept financing 6%

Liquidity 50%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-6.28%

1 Month

-20.68%

3 Months

-40.29%

6 Months

207.35%

1 Year

178.30%

2 Year

-50.24%

Key data

Stock price

$1.92

P/E Ratio

0.00

DAY RANGE

$1.88 - $1.92

EPS

$0.00

52 WEEK RANGE

$0.58 - $6.04

52 WEEK CHANGE

$175.00

MARKET CAP

2.341 M

YIELD

N/A

SHARES OUTSTANDING

860.721 K

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,635,127

AVERAGE 30 VOLUME

$945,071

Company detail

CEO: Geert C. PhD
Region: US
Website: phiopharma.com
Employees: 10
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. Company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT) PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression.

PHIO - Phio Pharmaceuticals Corp.